CMR in Myocardial Infarction with Nonobstructive Coronary Arteries (NCT06502899) | Clinical Trial Compass
CompletedNot Applicable
CMR in Myocardial Infarction with Nonobstructive Coronary Arteries
China387 participantsStarted 2019-01-01
Plain-language summary
MINOCA is accompanied by a worse prognosis, which is related to the inability to clarify the etiology.CMR has been explicitly recommended by guidelines as an etiologic diagnostic tool for MINOCA. Although CMR-related parameters, such as strain and ECV, have been shown to be associated with prognosis in patients with myocardial infarction. However, the relationship between CMR-strain or ECV and MINOCA is unclear. The aim of this study was to investigate the characterization of CMR-strain or ECV in patients with MINOCA and the relationship with prognosis.
Who can participate
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Complete CMR during hospitalization;
. CAG results suggesting coronary stenosis of less than 50%;
. peak hsTnT above the 99th percentile.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Primary endpoint events included any cause, non-fatal infarction, stroke, or cardiac readmission.
Timeframe: All patients were followed until June 30, 2024
Trial details
NCT IDNCT06502899
SponsorThe Affiliated Hospital of Xuzhou Medical University